Department of Life Sciences and Biotechnology, University of Ferrara, Italy; Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA.
Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA; Center for Biomedical Imaging, Clinical Translational Science Institute, University at Buffalo, State University of New York, Buffalo, NY, USA.
J Neurol Sci. 2019 Jan 15;396:36-41. doi: 10.1016/j.jns.2018.10.023. Epub 2018 Oct 28.
In multiple sclerosis (MS), several adhesion molecules are involved within the central nervous system in inflammatory and neurodegenerative processes that are associated to progressive disability and increasing brain atrophy. The neural cell adhesion molecule (NCAM) has been suggested to participate in the reparative mechanisms and in the remyelination processes, key issues in MS pathology. We aimed at investigating plasma levels of the seldom investigated soluble (s)NCAM, and as comparison those of intercellular adhesion molecule-1 (sICAM-1) and vascular adhesion molecule-1 (sVCAM-1), and their association with clinical and MRI measures of lesion volumes and of global and regional atrophy. The cross-sectional study was conducted in 85 relapsing-remitting (RR)-MS, 53 progressive (P)-MS patients, and 42 healthy individuals (HI). Correlation of MRI measures with plasma levels of these adhesion molecules were not observed. In the MS and HI groups, sNCAM levels were significantly and positively associated with sVCAM-1 levels. Differently, the correlation between sICAM-1 and sVCAM-1 was observed only in MS patients. sNCAM and sVCAM-1 levels were higher in P-MS compared to HI (P = 0.05 and P = 0.028 respectively). The sVCAM-1 levels differed (P < 0.001) among DMTs groups and HI. The association of sNCAM plasma levels with MS disease, as well as differences in sVCAM-1 levels in patients receiving different DMTs, deserve further investigation.
在多发性硬化症 (MS) 中，几种黏附分子参与中枢神经系统的炎症和神经退行性过程，这些过程与进行性残疾和脑萎缩增加有关。神经细胞黏附分子 (NCAM) 被认为参与修复机制和髓鞘再生过程，这是 MS 病理学中的关键问题。我们旨在研究很少研究的可溶性 (s)NCAM 的血浆水平，并将其与细胞间黏附分子-1 (sICAM-1) 和血管细胞黏附分子-1 (sVCAM-1) 进行比较，及其与病变体积和整体及区域性萎缩的临床和 MRI 测量值的关联。这项横断面研究纳入了 85 名复发缓解型 (RR)-MS 患者、53 名进展型 (P)-MS 患者和 42 名健康对照者 (HI)。MRI 测量值与这些黏附分子的血浆水平之间没有观察到相关性。在 MS 和 HI 组中，sNCAM 水平与 sVCAM-1 水平呈显著正相关。相反，仅在 MS 患者中观察到 sICAM-1 与 sVCAM-1 之间的相关性。与 HI 相比，P-MS 患者的 sNCAM 和 sVCAM-1 水平显著升高（P=0.05 和 P=0.028）。sVCAM-1 水平在不同 DMT 组和 HI 之间存在差异（P<0.001）。sNCAM 血浆水平与 MS 疾病的关联，以及接受不同 DMT 的患者的 sVCAM-1 水平的差异，值得进一步研究。
